Alaunos Therapeutics Inc (TCRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has a cash flow conversion efficiency ratio of -0.460x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-300.00K) by net assets ($652.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alaunos Therapeutics Inc (TCRT) total market value for the company's overall valuation and market capitalisation.
Alaunos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alaunos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alaunos Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Alaunos Therapeutics Inc earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Public Policy Holding Company Inc
LSE:PPHC
|
0.024x |
|
RevoluGROUP Canada Inc
V:REVO
|
-0.399x |
|
Optima Health plc
LSE:OPT
|
0.038x |
|
GRANITE CREEK COPPER
F:GRK
|
N/A |
|
Ophir Gold Corp
V:OPHR
|
-0.024x |
|
Railway Metrics & Dynamics Sweden AB
ST:RMDX
|
0.026x |
|
Southern Empire Resources Corp
V:SMP
|
0.139x |
|
INEO Tech Corp
V:INEO
|
2.714x |
Annual Cash Flow Conversion Efficiency for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Alaunos Therapeutics Inc from 2001 to 2025. View Alaunos Therapeutics Inc (TCRT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.15 Million | $-2.87 Million | -1.333x | +44.70% |
| 2024-12-31 | $2.06 Million | $-4.97 Million | -2.410x | +49.58% |
| 2023-12-31 | $6.31 Million | $-30.14 Million | -4.779x | -530.33% |
| 2022-12-31 | $38.55 Million | $-29.23 Million | -0.758x | +28.39% |
| 2021-12-31 | $58.06 Million | $-61.47 Million | -1.059x | -130.24% |
| 2020-12-31 | $123.98 Million | $-57.01 Million | -0.460x | -6.94% |
| 2019-12-31 | $95.01 Million | $-40.85 Million | -0.430x | +25.61% |
| 2018-12-31 | $85.56 Million | $-49.46 Million | -0.578x | -202.35% |
| 2017-12-31 | $-96.81 Million | $-54.67 Million | 0.565x | -25.16% |
| 2016-12-31 | $-77.30 Million | $-58.33 Million | 0.755x | +659355.55% |
| 2015-12-31 | $87.37 Million | $-10.00K | 0.000x | +99.99% |
| 2014-12-31 | $33.84 Million | $-36.65 Million | -1.083x | +10.13% |
| 2013-12-31 | $49.38 Million | $-59.51 Million | -1.205x | +25.95% |
| 2012-12-31 | $48.45 Million | $-78.83 Million | -1.627x | -200.04% |
| 2011-12-31 | $71.61 Million | $-38.84 Million | -0.542x | +15.86% |
| 2010-12-31 | $30.55 Million | $-19.69 Million | -0.645x | -47.35% |
| 2009-12-31 | $28.10 Million | $-12.29 Million | -0.437x | +87.47% |
| 2008-12-31 | $6.74 Million | $-23.52 Million | -3.490x | -389.56% |
| 2007-12-31 | $30.37 Million | $-21.65 Million | -0.713x | -31.16% |
| 2006-12-31 | $26.53 Million | $-14.42 Million | -0.544x | +55.42% |
| 2005-12-31 | $7.20 Million | $-8.78 Million | -1.219x | -450.55% |
| 2004-12-31 | $-21.02K | $-7.31K | 0.348x | -4.28% |
| 2003-12-31 | $-25.69K | $-9.33K | 0.363x | -46.49% |
| 2002-12-31 | $-17.33K | $-11.77K | 0.679x | -94.13% |
| 2001-12-31 | $-2.62K | $-30.26K | 11.570x | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more